NEW YORK, August 12, 2021 / PRNewswire / – miR Scientific, LLC Announces Appointment of Erik Johnson, a seasoned leader in pharmacy and oncology, as COO. This appointment advances a key element of the Company’s expansion towards the global commercialization of its first product, the miR SentinelÂ® Prostate Cancer test – a premium, a non-invasive, self-contained urinary fluid biopsy test for the detection, classification and monitoring of prostate cancer. Mr Johnson joins miR Scientific from Bristol Myers Squibb (BMS), where he was instrumental in leading the global commercial scale-up of two breakthrough immuno-oncology programs. Erik will work closely with the co-founder, president and CEO Sam salman directing the company’s global operations, logistics and corporate resources for the high-volume, planned production required by miR Scientific to carry out its mission to transform cancer management worldwide.
Mr. Johnson has held a number of senior positions at BMS, including leadership roles in strategy, planning, operations and sales. As Global Sales Manager, Melanoma and Genitourinary (GU) Immuno-Oncology, he was the Global Head of OpdivoÂ® and YervoyÂ® in these tumors, while also managing pipeline assets for melanoma and UG indications, totaling over $ 5 billion in annual turnover. Throughout his tenure at BMS, Erik launched products for seven new indications, each exceeding company expectations. As a brand leader for SPRYCELÂ®, he drove and executed a strategy that generated double-digit year-over-year growth, leading the brand to record levels of sales and market share.
âErik’s track record as a leader in oncology and in terms of positive impact on patient outcomes complements his decades of proven commitment to strategic leadership based on principle and integrity,â said declared Sam salman. âWe define successful disease management transformation as achieving multi-stakeholder validation and equitable global accessibility to our portfolio of innovative products. As such, we were looking for proven leadership in the field of large pharmaceutical companies well accustomed to rapidly reaching and maintaining global scale, which we can combine with our current diagnostic and impact capabilities. âThe emphasis by miR Scientific on Impact includes measuring its environmental, social and governance (ESG) metrics and mapping its contributions to the United Nations Sustainable Development Goals (SDGs).
âJoining the miR Scientific leadership team with the broad mandate to achieve the operational excellence required to deliver on our commitment to innovation and global market leadership in disease management represents an extraordinary opportunity to have a measurable impact for patients around the world, âsaid Erik Johnson. âI look forward to working with our colleagues from United States, Israel, Canada, and Porto Rico, as well as with our three co-founders, including Rob tenniswood, my predecessor who skillfully led operations since the founding of miR Scientific, and with Martin Tenniswood Ph.D., our Chief Scientist. “
The Company is also pleased to announce that Rob tenniswood, co-founder and first COO of miR Scientific, will be promoted to the position of Executive Vice President, and will continue to report and work closely with the President and CEO, Sam salman.
About miR Scientifique:
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate disease detection, characterization and surveillance. The Company developed the miR disease management platformÂ®, a proprietary and non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform is powered by the miR SentinelÂ® Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on interrogation of small, non-coding RNAs extracted from urinary exosomes. miR Scientific is developing interoperable products and services needed to revolutionize the standards of care supporting urologic oncology, including prostate, bladder and other urothelial cancers. These new standards are urgently needed given the prevalence of these cancers and their debilitating burden around the world. miR Scientific is an operating subsidiary majority owned by Impact NRS LLC, headquartered in New York with operating subsidiaries in Israel, Canada and Puerto Rico.
+1 (781) 235-3060
SOURCE miR Scientific, LLC